|
1
|
Onciu M: Acute lymphoblastic leukemia.
Hematol Oncol Clin North Am. 23:655–674. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Woo JS, Alberti MO and Tirado CA:
Childhood B-acute lymphoblastic leukemia: A genetic update. Exp
Hematol Oncol. 3:162014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chiarini F, Lonetti A, Evangelisti C,
Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM,
McCubrey JA and Martelli AM: Advances in understanding the acute
lymphoblastic leukemia bone marrow microenvironment: From biology
to therapeutic targeting. Biochim Biophys Acta. 1863:449–463. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pui CH, Carroll WL, Meshinchi S and Arceci
RJ: Biology, risk stratification, and therapy of pediatric acute
leukemias: An update. J Clin Oncol. 29:551–565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hangai M, Watanabe K, Shiozawa R, Hiwatari
M, Ida K and Takita J: Relapsed acute lymphoblastic leukemia with
unusual multiple bone invasions: A case report. Oncol Lett.
7:991–993. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colombo MP and Piconese S:
Regulatory-T-cell inhibition versus depletion: The right choice in
cancer immunotherapy. Nat Rev Cancer. 7:880–887. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oleinika K, Nibbs RJ, Graham GJ and Fraser
AR: Suppression, subversion and escape: The role of regulatory T
cells in cancer progression. Clin Exp Immunol. 171:36–45. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Facciabene A, Motz GT and Coukos G:
T-regulatory cells: Key players in tumor immune escape and
angiogenesis. Cancer Res. 72:2162–2171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu J, Yamane H and Paul WE:
Differentiation of effector CD4 T cell populations (*). Annu Rev
Immunol. 28:445–489. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rudensky AY: Regulatory T cells and Foxp3.
Immunol Rev. 241:260–268. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shevach EM: Mechanisms of foxp3+ T
regulatory cell-mediated suppression. Immunity. 30:636–645. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peters JM and Ansari MQ: Multiparameter
flow cytometry in the diagnosis and management of acute leukemia.
Arch Pathol Lab Med. 135:44–54. 2011.PubMed/NCBI
|
|
13
|
Subspecialty Group of Hematology Diseases;
The Society of Pediatrics; Chinese Medical Association; Editorial
Board; Chinese Journal of Pediatrics. Recommendations for diagnosis
and treatment of acute lymphoblastic leukemia in childhood (3rd
revised version). Zhonghua Er Ke Za Zhi. 44:392–395. 2006.(In
Chinese). PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamamoto T, Yanagimoto H, Satoi S,
Toyokawa H, Hirooka S, Yamaki S, Yui R, Yamao J, Kim S and Kwon AH:
Circulating CD4+CD25+ regulatory T cells in patients with
pancreatic cancer. Pancreas. 41:409–415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Beyer M, Classen S, Endl E, Kochanek M,
Weihrauch MR, Debey-Pascher S, Knolle PA and Schultze JL:
Comparative approach to define increased regulatory T cells in
different cancer subtypes by combined assessment of CD127 and
FOXP3. Clin Dev Immunol. 2011:7340362011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shenghui Z, Yixiang H, Jianbo W, Kang Y,
Laixi B, Yan Z and Xi X: Elevated frequencies of CD4+
CD25+ CD1271o regulatory T cells is associated to poor
prognosis in patients with acute myeloid leukemia. Int J Cancer.
129:1373–1381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weiss L, Melchardt T, Egle A, Grabmer C,
Greil R and Tinhofer I: Regulatory T cells predict the time to
initial treatment in early stage chronic lymphocytic leukemia.
Cancer. 117:2163–2169. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li AH, Qiu GQ, Gu WY, Ling Y, Weng KZ, Tan
Q and Cao XS: Expression of CD4+ CD25+ regulatory T cells in the
patients with acute lymphocytic leukemia. Xi Bao Yu Fen Zi Mian Yi
Xue Za Zhi. 23:439–442. 2007.(In Chinese). PubMed/NCBI
|
|
20
|
Wu CP, Qing X, Wu CY, Zhu H and Zhou HY:
Immunophenotype and increased presence of CD4(+)CD25(+) regulatory
T cells in patients with acute lymphoblastic leukemia. Oncol Lett.
3:421–424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lal G, Zhang N, van der Touw W, Ding Y, Ju
W, Bottinger EP, Reid SP, Levy DE and Bromberg JS: Epigenetic
regulation of Foxp3 expression in regulatory T cells by DNA
methylation. J Immunol. 182:259–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng G, Yu A, Dee MJ and Malek TR: IL-2R
signaling is essential for functional maturation of regulatory T
cells during thymic development. J Immunol. 190:1567–1575. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rouse M, Nagarkatti M and Nagarkatti PS:
The role of IL-2 in the activation and expansion of regulatory
T-cells and the development of experimental autoimmune
encephalomyelitis. Immunobilogy. 218:674–682. 2013. View Article : Google Scholar
|
|
24
|
Schlenner SM, Weigmann B, Ruan Q, Chen Y
and von Boehmer H: Smad3 binding to the foxp3 enhancer is
dispensable for the development of regulatory T cells with the
exception of the gut. J Exp Med. 209:1529–1535. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rahimi RA and Leof EB: TGF-beta signaling:
A tale of two responses. J Cell Biochem. 102:593–608. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Klunker S, Chong MM, Mantel PY, Palomares
O, Bassin C, Ziegler M, Rückert B, Meiler F, Akdis M, Littman DR
and Akdis CA: Transcription factors RUNX1 and RUNX3 in the
induction and suppressive function of Foxp3+ inducible regulatory T
cells. J Exp Med. 206:2701–2715. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liao W, Lin JX and Leonard WJ:
Interleukin-2 at the crossroads of effector responses, tolerance,
and immunotherapy. Immunity. 38:13–25. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Q, Kim YC, Laurence A, Punkosdy GA
and Shevach EM: IL-2 controls the stability of Foxp3 expression in
TGF-beta-induced Foxp3+ T cells in vivo. J Immunol. 186:6329–6337.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mahmud SA, Manlove LS and Farrar MA:
Interleukin-2 and STAT5 in regulatory T cell development and
function. JAKSTAT. 2:e231542013.PubMed/NCBI
|
|
30
|
Classen S, Zander T, Eggle D, Chemnitz JM,
Brors B, Büchmann I, Popov A, Beyer M, Eils R, Debey S and Schultze
JL: Human resting CD4+ T cells are constitutively inhibited by TGF
beta under steady-state conditions. J Immunol. 178:6931–6940. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Delisle JS, Giroux M, Boucher G, Landry
JR, Hardy MP, Lemieux S, Jones RG, Wilhelm BT and Perreault C: The
TGF-β-Smad3 pathway inhibits CD28-dependent cell growth and
proliferation of CD4 T cells. Genes Immun. 14:115–126. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seoane J and Gomis RR: TGF-β family
signaling in tumor suppression and cancer progression. Cold Spring
Harb Perspect Biol. 9:a0222772017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Principe DR, Doll JA, Bauer J, Jung B,
Munshi HG, Bartholin L, Pasche B, Lee C and Grippo PJ: TGF-β:
Duality of function between tumor prevention and carcinogenesis. J
Natl Cancer Inst. 106:djt3692014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bruno L, Mazzarella L, Hoogenkamp M,
Hertweck A, Cobb BS, Sauer S, Hadjur S, Leleu M, Naoe Y, Telfer JC,
et al: Runx proteins regulate Foxp3 expression. J Exp Med.
206:2329–2337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Neurath MF and Finotto S: IL-6 signaling
in autoimmunity, chronic inflammation and inflammation-associated
cancer. Cytokine Growth Factor Rev. 22:83–89. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun Q, Liu Q, Zheng Y and Cao X: Rapamycin
suppresses TLR4-triggered IL-6 and PGE(2) production of colon
cancer cells by inhibiting TLR4 expression and NF-kappaB
activation. Mol Immunol. 45:2929–2936. 2008. View Article : Google Scholar : PubMed/NCBI
|
